DELETION 13Q BY FISH

 The Deletion 13q test, performed using Fluorescence In Situ Hybridization (FISH), is used to detect the loss of genetic material on the long arm of chromosome 13. This deletion is commonly associated with certain hematological malignancies such as chronic lymphocytic leukemia (CLL), multiple myeloma, and other cancers. It helps in risk stratification and guides therapeutic decisions.

 This test is usually ordered for patients diagnosed with CLL or multiple myeloma to assess prognosis. It is also relevant in patients with other suspected chromosomal abnormalities or when initial karyotyping reveals potential deletions involving chromosome 13.

 A blood or bone marrow sample is collected, and the cells are processed in the laboratory using FISH technology. Fluorescent probes specific to the 13q region are used to detect the presence or absence of genetic material in that area, providing a visual confirmation under a fluorescence microscope.

 A positive result for 13q deletion suggests that part of the genetic material on chromosome 13 is missing. In CLL, this deletion is often associated with a more favorable prognosis if it is an isolated finding. However, when it occurs alongside other genetic abnormalities, it may indicate a more complex disease course.

 Yes, the presence or absence of the 13q deletion can guide treatment planning and risk assessment. In some cases, patients with this deletion may be monitored without immediate therapy, while others may require more aggressive treatment depending on their overall genetic profile and clinical symptoms.